PHR Phreesia, Inc.
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.…
Industry Peers
Health Information ServicesKey Statistics
About Phreesia (NYSE: PHR)
›
Phreesia (NYSE: PHR) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 1,789 employees.
The shares were at 11.87 USD on 19 November 2026, down 45.5% over 52 weeks. Its 52-week range is 7.770 USD to 21.77 USD: the price is 45.5% below the high and 52.8% above the low.
At a market capitalisation of 736.78M USD, it trades at 69.8 times trailing earnings and 7.5 times forward earnings. The median trailing P/E of its 14 largest Health Information Services peers is 40.2, a premium of 74% for PHR.
Phreesia reports return on equity of 0.7%, an operating margin of 4.3% and revenue up 10.4% year over year.
It holds more cash than debt, a net cash position of 5.00M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 15 analysts cover the stock, with an average rating of Buy; their mean price target of 13.87 USD is 16.8% above the current price. The next earnings report is expected on 2 December 2026.